Table 1 Characteristics of the patients included or non included in Group 1 and Group 2

Demographics

   Age at biopsy, mean (se), years

52.8 (0.87)

54.9 (1.47)

0.18

48.5 (1.28)

49.1 (1.45)

0.18

0.01

   Male, n (%)

98 (58)

39 (63)

57 (59)

38 (69)

0.64

0.86

Metabolic factor (%)

   Diabetes

61/170 (36)

10/62 (16)

0.004

31/97 (32)

8/97 (12)

0.62

0.001

   Arterial Hypertension

53/170 (31)

6/62 (10)

0.14

15/97 (16)

16/97 (23)

0.21

0.001

   BMI greater than 27 kg/m²

85/141 (60)

12/21 (57)

0.78

43/97 (44)

22/97 (32)

0.11

0.42

   Triglycerides greater than 1.5

68/161 (42)

17/42 (40)

0.87

35/97 (36)

15/97 (22)

0.047

0.33

   HDL cholesterol lower than 40 mg/L

36/151 (24)

6/38 (16)

0.29

15/94 (16)

15/66 (23)

0.28

0.14

   Metabolic factor

   None

21/170 (24)

34/62 (55)

P < 0.0001

P < 0.0001

   At least one

134/170 (79)

28/62 (45)

Alcohol consumption, n (%)

   No

118/170 (69)

51/62 (79)

0.63

57/97 (59)

41/69 (59)

0.63

0.20

   Yes

52/170 (31)

11/62 (21)

40/97 (41)

28/69 (41)

Fibrosis stage, n (%)

   Non advanced fibrosis

130/170 (76)

59/60(98)

0.001

66/97(68)

51/69(74)

0.48

0.13

No fibrosis (F0)

77/170 (45)

39/60 (65)

26/97 (27)

21/69 (30)

Perisinusoidal or periportal (F1)

54/170 (31)

20/60 (33)

40/97 (41)

30/69 (43)

1A: mild, zone 3, perisinusoidal

29/170 (17)

19/60 (31)

18/97 (19)

18/69 (25)

1B: moderate, zone 3, perisinusoidal

2/170 (1)

1/60 (2)

0/97 (0)

22/97 (22)

0/69 (0)

12/69 (18)

1C: portal/periportal

22/170 (13)

0/60 (0)

31/97 (32)

18/69(26)

Advanced Fibrosis

40/170 (24)

1/60(2)

15/97 (15)

13/69 (19)

Perisinusoidal and portal/periportal (F2)

20/170 (12)

11/170 (7)

0/60 (0)

0/60 (0)

12/97 (12)

4/97 (4)

2/69 (3)

3/69 (4)

   Bridging (F3)

9/170 (5)

1/60 (2)

   Cirrhosis (F4)

Non alcoholo-steato-hepatitis, n (%)

   No

75/170 (44)

25/60 (41)

0.15

29/97 (30)

40/69(58)

0.001

0.003

   Borderline (Probable)

67/170 (39)

26/60 (44)

35/97 (36)

19/69 (28)

   Yes

28/170 (17)

9/60 (15)

33/97 (34)

10/69 (14)

Steatosis

Histology

   Absence or <5%

22/170 (13)

12/60 (20)

0.38

19/97 (20)

13/69 (19)

0.38

0.22

   6–32

57/170 (34)

14/60 (23)

22/97 (23)

27/69 (39)

   33–65

43/170 (25)

16/60 (27)

27/97 (28)

10/69 (14)

   66–100

48/170 (28)

18/60 (30)

29/97 (30)

19/60 (28)

Interval between biopsy and serum,

   median

0

-100

<0.001

0

0

0.90

0.07

   (95%CI),

[0; 1]

[-215; 0]

[0; 0]

[0; 0]

   Range days

-87;+89

-538; +540

-24;+49

-42; +40

Biopsy quality mean (se)

   Sample size

20.0 (0.5)

19.7 (0.9)

0.68

17.8 (0.7)

21.4 (0.9)

0.001

0.007

   Number of fragment

2.3 (0.2)

2.3 (0.2)

0.41

2.3 (0.2)

2.2 (0.2)

0.76

0.52

   Number of portal tracts

16.3 (0.6)

16.3 (1.1)

0.79

13.6 (0.6)

17.1 (1.0)

0.008

0.01

Serum biochemical markers, mean (se)

   α₂-macroglobulin ^(g/L)

1.68 (0.05)

1.78 (0.11)

0.26

1.72 (0.06)

1.76 (0.08)

0.47

0.38

   ALT (IU)

71 (3)

64 (6)

0.26

79 (5)

84 (10)

0.64

0.23

   AST (IU) ^†

50 (3)

42 (3)

0.10

45 (3)

52 (5)

0.10

0.009

   Apolipoprotein A1(g/L)

1.47 (0.03)

1.46 (0.07)

0.84

1.59 (0.07)

1.53 (0.04)

0.80

0.07

   GGT (IU/L)

110 (11)

113 (19)

0.96

132 (12)

158 (19)

0.96

0.03

   Haptoglobin (g/L)

1.10 (0.04)

1.19 (0.15)

0.69

1.12 (0.10)

1.02 (0.05)

0.16

0.28

   Total bilirubin (μmol/L)

14.5 (3.1)

12.8 (2.0)

0.43

12.6 (0.6)

13.6 (1.0)

0.89

0.64

   FibroTest (0.00–1.00)

0.30 (0.02)

0.37 (0.05)

0.18

0.29 (0.02)

0.33 (0.02)

0.21

0.84

   ActiTest (0.00–1.00)

0.39 (0.02)

0.34 (0.04)

0.24

0.41 (0.02)

0.43 (0.03)

0.55

0.26